Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Wen Lei^#^{1

2}, Hui Liu^#¹, Wenhai Deng^#³, Wei Chen^#⁴, Yun Liang¹, Wenxia Gao⁴, Xianggui Yuan¹, Shanshan Guo¹, Ping Li⁵, Jinyong Wang⁶, Xiangmin Tong⁷, Yi Eve Sun⁸, Aibin Liang⁹, Wenbin Qian^{10

11}

Affiliations

¹ Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
² Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education; Biotherapy Research Center, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
³ Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
⁴ Stem Cell Translational Research Center, Tongji Hospital, Tongji University, School of Medicine, Shanghai, China.
⁵ Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China.
⁶ State Key Laboratory of Stem Cell and Reproductive Biology, Institute for Stem Cell and Regeneration, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
⁷ Department of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China. tongxiangmin@163.com.
⁸ Stem Cell Translational Research Center, Tongji Hospital, Tongji University, School of Medicine, Shanghai, China. yi.eve.sun@gmail.com.
⁹ Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China. lab7182@tongji.edu.cn.
¹⁰ Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. qianwb@zju.edu.cn.
¹¹ Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education; Biotherapy Research Center, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. qianwb@zju.edu.cn.

^# Contributed equally.

PMID: 40610723
PMCID: PMC12296552
DOI: 10.1038/s43018-025-01026-w

Published Erratum

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Wen Lei et al. Nat Cancer. 2025 Jul.

. 2025 Jul;6(7):1295.

doi: 10.1038/s43018-025-01026-w.

Authors

Affiliations

¹ Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
² Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education; Biotherapy Research Center, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
³ Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
⁴ Stem Cell Translational Research Center, Tongji Hospital, Tongji University, School of Medicine, Shanghai, China.
⁵ Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China.
⁶ State Key Laboratory of Stem Cell and Reproductive Biology, Institute for Stem Cell and Regeneration, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
⁷ Department of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China. tongxiangmin@163.com.
⁸ Stem Cell Translational Research Center, Tongji Hospital, Tongji University, School of Medicine, Shanghai, China. yi.eve.sun@gmail.com.
⁹ Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China. lab7182@tongji.edu.cn.
¹⁰ Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. qianwb@zju.edu.cn.
¹¹ Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education; Biotherapy Research Center, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. qianwb@zju.edu.cn.

^# Contributed equally.

PMID: 40610723
PMCID: PMC12296552
DOI: 10.1038/s43018-025-01026-w

No abstract available

PubMed Disclaimer

Erratum for

Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.
Lei W, Liu H, Deng W, Chen W, Liang Y, Gao W, Yuan X, Guo S, Li P, Wang J, Tong X, Sun YE, Liang A, Qian W. Lei W, et al. Nat Cancer. 2025 May;6(5):786-800. doi: 10.1038/s43018-025-00940-3. Epub 2025 Apr 18. Nat Cancer. 2025. PMID: 40251398 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Affiliations

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials